Loading...
NPI 1477876514 · Cedar Rapids, IA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medical Laboratories Of Eastern Iowa Lc is a clinical medical laboratory provider located in Cedar Rapids, Iowa. This profile covers 214 Medicare and 177 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medical Laboratories Of Eastern Iowa Lc |
| Address | 855 A Ave Ne |
| City | Cedar Rapids |
| State | IA |
| ZIP | 52402 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 3, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $14.4M |
| Medicare | $1.4M |
MEDICAL LABORATORIES OF EASTERN IOWA LC operates as a high-volume clinical diagnostic lab with an emphasis on both routine phlebotomy and molecular infectious-disease testing; Medicare top codes include 36415 (phlebotomy), lipid panels (80061), and TSH testing (84443), while Medicaid volumes are dominated by molecular/PLA respiratory and pathogen panels (U0003, 0202U, 87651) indicating a dual focus on standard outpatient chemistry/hematology plus large-scale molecular respiratory testing. The mix of codes suggests the business combines specimen collection and high-throughput lab analytics rather than only point-of-care or clinic-based testing.
Revenue concentration differs markedly by payer: precomputed metrics show the top three Medicare codes account for 34.7% of Medicare revenue, concentrating Medicare dollars in a small set of routine lab services, while the top three Medicaid codes account for 42.1% of Medicaid revenue, signaling even greater dependence on a few high-revenue Medicaid tests driven by molecular respiratory panels. These precomputed shares point to material revenue sensitivity if volume or reimbursement for those leading codes changes.
The provider’s payer mix is highly skewed toward Medicaid in scale: reported lifetime revenue is $1.4M from Medicare versus $14.4M from Medicaid, indicating Medicaid is the dominant revenue source. This profile makes the lab particularly exposed to Medicaid policy, contracting, and state-level test demand dynamics in Iowa.
On competitive standing, the provider is a major statewide player for many Medicaid codes: for example, U0003 ranks #3 of 64 in-state and is labeled an "extreme outlier, far above typical state volume," 0202U ranks #2 in-state with notably above typical volume, and 87651 ranks #1 of 167 and is an extreme outlier. Those ranks indicate market-leading volume for molecular respiratory and pathogen testing within Iowa. Conversely, Medicare ranks for several routine codes (e.g., 36415 rank #135 of 86467, 80061 rank #181 of 21671) place the provider at very high national percentiles for volume on common collection and chemistry tests, showing unusually large Medicare testing volumes relative to most labs.
Several specific codes are statistical outliers in-state on Medicaid, reflecting specialization in multiplex and proprietary respiratory testing: 0202U (PLA respiratory panel) and 0241U/0240U appear as #1 or #2 in-state and are described as extreme outliers or notably above typical state volume, while U0003 is an extreme outlier as well. These labels and ranks imply the lab handles exceptionally large quantities of respiratory and multiplex molecular tests compared with other Iowa providers, consistent with a reference- or regional testing role for those assays.
On Medicare, the lab also shows concentrated high-volume activity for specimen collection and common panels: 36415 (phlebotomy) accounts for $147K and 14.6% of Medicare revenue and ranks in the 100th percentile nationally for volume on that code, and other routine panels (80061, 84443, 80053, 80048) appear at very high national percentiles. This pattern supports an operational model that includes large outpatient draw sites or broad contract relationships with ordering providers.
Tenure is long enough to establish clinical operations: the NPI was enumerated on 2010-03-03 (~16 years ago), indicating sustained presence in the market and time to scale both routine testing and the molecular respiratory services now reflected in Medicaid billing. That duration aligns with the provider’s developed in-state market position for specialized panels.
From a risk/operational planning perspective, the lab’s combination of concentrated revenue in a few Medicaid molecular/PLA codes (top-3 share 42.1%) and high national percentiles on numerous Medicare routine-test codes (top-3 share 34.7%) suggests that changes in Medicaid reimbursement, contract status for high-value PLA tests, or shifts in respiratory testing demand could disproportionately impact overall revenue. Payers and analysts should monitor contract terms for proprietary assays and state Medicaid coverage for high-volume molecular tests given the provider’s outsized Medicaid exposure.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
214 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 18,380 | $10 | $147K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 7,880 | $10 | $102.5K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 6,270 | $20 | $100.3K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 7,080 | $10 | $70.8K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 8,690 | $10 | $69.5K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 6,130 | $10 | $55.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 6,750 | $10 | $54K |
| 0240U | N/A | 330 | $140 | $45.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 1,550 | $30 | $44.9K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 1,100 | $40 | $43.9K |
Showing 1–10 of 214
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 214 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
177 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 26,580 | $80 | $2M |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 4,630 | $390 | $1.8M |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 34,670 | $30 | $1.1M |
| 0241U | N/A | 5,730 | $130 | $756.6K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 4,820 | $140 | $651.1K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 4,050 | $130 | $522.8K |
| 0240U | N/A | 4,120 | $120 | $498.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 18,600 | $20 | $427.8K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 8,070 | $50 | $371.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9,220 | $40 | $359.6K |
Showing 1–10 of 177
How this provider's Medicaid billing volume and revenue compare to other Iowa providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Iowa median
177 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 2 | 10 | 330 | $360 | $286.9K |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 2 | 50 | 130 | $320 | $224.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 60 | 210 | $80 | $186.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 82 | 90 | 740 | $60 | $155.6K |
| 99001 | The provider prepares a specimen collected from a patient at a location other than the provider’s office and sends it to an outside laboratory for analysis. | 6 | 10 | 110 | $40 | $116.1K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 7 | 20 | 660 | $20 | $104.8K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 2 | 30 | 150 | $110 | $96.1K |
| 0241U | N/A | 1 | 80 | 290 | $110 | $85.1K |
| 0240U | N/A | 1 | 20 | 200 | $120 | $84.2K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 9 | 20 | 890 | $30 | $80.7K |
Showing 1–10 of 177
Other providers in the same ZIP code as Medical Laboratories Of Eastern Iowa Lc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.